Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene Symbol | FLT3 | ||||||||||
Synonyms | CD135 | FLK-2 | FLK2 | STK1 | ||||||||||
Gene Description | FLT3, fms related receptor tyrosine kinase 3, activates Akt, Ras, and Erk pathways to regulate differentiation, proliferation, and survival of hematopoietic progenitor cells (PMID: 29316714, PMID: 28538663). Activating mutations of FLT3 are common in hematologic tumors (PMID: 19467916) and the internal tandem duplication (ITD) mutation is commonly observed in acute myeloid leukemia (PMID: 30181385, PMID: 32241850). | ||||||||||
|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00887068 | Phase III | Azacitidine | Randomized Allogeneic Azacitidine Study | Completed | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT02829840 | Phase Ib/II | Azacitidine + Ponatinib | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT04140487 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT02323607 | Phase I | Cytarabine + Daunorubicin + Pacritinib Decitabine + Pacritinib | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | Completed | USA | 0 |
NCT05010200 | Phase I | CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) | Active, not recruiting | USA | 0 |
NCT04214249 | Phase II | Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03709758 | Phase I | Cytarabine + Daunorubicin + Venetoclax | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML | Recruiting | USA | 0 |
NCT02381548 | Phase I | Adavosertib + Belinostat | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03836209 | Phase II | Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02634827 | Phase II | Decitabine + Midostaurin | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | Terminated | USA | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT06022003 | Phase II | Azacitidine + Gilteritinib | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects >=18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR) | Recruiting | FRA | 0 |
NCT03701295 | Phase Ib/II | Azacitidine + Pinometostat | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Completed | USA | 0 |
NCT04051996 | Phase II | Decitabine + Glasdegib | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03070093 | Expanded access | Gilteritinib | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | Approved for marketing | USA | CAN | 1 |
NCT05279859 | Phase Ib/II | ERAS-007 + Gilteritinib | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) | Withdrawn | USA | 0 |
NCT03625505 | Phase I | Gilteritinib + Venetoclax | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03620318 | Expanded access | Crenolanib | Individual Patient Compassionate Use of Crenolanib | Available | ITA | 0 |
NCT02723435 | Phase II | Midostaurin | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Withdrawn | 0 | |
NCT04491084 | Phase Ib/II | CDX-1140 + CDX-301 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (FLT3) | Terminated | USA | 0 |
NCT02747537 | Phase II | Irinotecan + Sorafenib | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | Withdrawn | 0 | |
NCT03591510 | Phase II | Cytarabine Cytarabine + Etoposide Cytarabine + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Cytarabine + Daunorubicin + Fludarabine Cytarabine + Daunoxome + Fludarabine Midostaurin | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | Recruiting | USA | TUR | SVN | POL | ITA | GRC | DEU | CZE | AUT | 4 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |
NCT03114228 | Expanded access | Midostaurin | An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | No longer available | CAN | 0 |
NCT02400281 | Phase Ib/II | Azacitidine Crenolanib Cytarabine + Idarubicin | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | Completed | USA | 0 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04223596 | Phase II | Brigatinib | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) | Active, not recruiting | ESP | 0 |
NCT02624570 | Phase I | Midostaurin | Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. | No longer available | USA | 0 |
NCT04801797 | Phase II | Azacitidine + Venetoclax Cytarabine + Idarubicin Cytarabine + Daunoxome Cytarabine + Daunorubicin | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | Recruiting | USA | 0 |
NCT03194685 | Phase Ib/II | FF-10101 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04616248 | Phase I | CDX-1140 + CDX-301 + Poly ICLC | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
NCT02530476 | Phase Ib/II | Selinexor + Sorafenib | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
NCT02756962 | Phase II | Midostaurin Cytarabine | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | Active, not recruiting | USA | 0 |
NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
NCT03730012 | Phase Ib/II | Atezolizumab + Gilteritinib | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02532231 | Phase II | Nivolumab | Nivolumab in AML in Remission at High Risk for Relapse | Completed | USA | 0 |
NCT02126553 | Phase II | Lenalidomide | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | Completed | USA | 0 |
NCT02270788 | Phase I | Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT01883362 | Phase II | Midostaurin | Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | Completed | USA | CAN | 0 |
NCT04982354 | Phase Ib/II | Busulfan + CPX-351 + Fludarabine + Melphalan + Midostaurin | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT04409639 | Phase II | Cobimetinib | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) | Recruiting | USA | 0 |
NCT03825796 | Phase II | CPX-351 + Enasidenib Cytarabine + Enasidenib Enasidenib | CPX-351 Plus Enasidenib for Relapsed AML | Active, not recruiting | USA | 0 |
NCT02418000 | Phase Ib/II | E6201 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation | Terminated | USA | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT04536077 | Phase II | CDX-1140 + CDX-301 CDX-1140 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Terminated | USA | 0 |
NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT06001788 | Phase I | Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05028751 | Phase Ib/II | Gilteritinib + Lanraplenib | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | ESP | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT04631744 | Phase II | Cabozantinib | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
NCT05658640 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT02283177 | Phase II | Crenolanib + Cytarabine + Daunorubicin | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | Completed | USA | 0 |
NCT01657682 | Phase II | Crenolanib | A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | Completed | USA | 0 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Active, not recruiting | USA | 0 |
NCT03900949 | Phase I | Midostaurin Cytarabine Cytarabine + Gemtuzumab ozogamicin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03701308 | Phase II | Cytarabine + Daunorubicin Cytarabine + Uproleselan Cytarabine + Daunorubicin + Uproleselan Cytarabine | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | Active, not recruiting | USA | 0 |
NCT02421939 | Phase III | Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | 3 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT05904106 | Phase II | Cytarabine Azacitidine + Venetoclax Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Cytarabine + Mitoxantrone | Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT) | Not yet recruiting | DEU | 0 |
NCT05886049 | Phase I | Cytarabine + Daunorubicin + Revumenib | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Recruiting | USA | 0 |
NCT04817241 | Phase Ib/II | Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | Active, not recruiting | USA | 0 |
NCT04385290 | Phase Ib/II | Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) | Recruiting | DEU | 0 |
NCT05330377 | Phase I | Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | Withdrawn | USA | 0 |
NCT05558124 | Phase I | CPX-351 + Gemtuzumab ozogamicin | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Recruiting | USA | 0 |
NCT04027309 | Phase III | Midostaurin Gilteritinib | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT05756777 | Phase I | Gilteritinib + Ivosidenib Enasidenib + Gilteritinib | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT04168502 | Phase III | Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin | Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML | Recruiting | ITA | 0 |
NCT05697510 | Phase I | Siltuximab | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM) | Recruiting | FRA | 0 |
NCT06152809 | Phase I | Aldesleukin + CIML-NK cells + Venetoclax | CIML NK Cells With Venetoclax for AML | Active, not recruiting | USA | 0 |
NCT06222580 | Phase I | Gilteritinib + Revumenib | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | Recruiting | USA | 0 |
NCT06313437 | Phase I | Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib | Revumenib in Combination With 7+3 + Midostaurin in AML | Not yet recruiting | USA | 0 |
NCT03922100 | Phase Ib/II | NMS-P088 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Terminated | ITA | FRA | ESP | 0 |
NCT05024552 | Phase I | CPX-351 + Gilteritinib | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | Recruiting | USA | 0 |
NCT05766514 | Phase II | Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | Not yet recruiting | USA | 0 |
NCT05554393 | Phase II | Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Recruiting | USA | CAN | 1 |
NCT05554406 | Phase II | Cytarabine + Daunorubicin Azacitidine + Venetoclax CPX-351 Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Recruiting | USA | 1 |
NCT06366789 | Phase I | ZE46-0134 | Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | AUS | 0 |
NCT05599360 | Phase II | CPX-351 + Gemtuzumab ozogamicin | Vyxeos for Induction of Low- or Intermediate-risk. | Recruiting | ISR | 0 |
NCT04518345 | Phase Ib/II | Dubermatinib Azacitidine + Dubermatinib | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04493138 | Phase Ib/II | Azacitidine + Quizartinib | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Recruiting | USA | 0 |
NCT04655391 | Phase I | Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | Withdrawn | USA | 0 |
NCT04107727 | Phase II | Cytarabine Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Quizartinib Cytarabine + Quizartinib | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | Unknown status | ESP | 0 |
NCT03735875 | Phase Ib/II | Quizartinib + Venetoclax | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT05183035 | Phase III | Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin + Venetoclax Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Recruiting | USA | SWE | NZL | NOR | NLD | ITA | ISR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 1 |
NCT03365661 | Phase II | Nogapendekin alfa inbakicept | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Withdrawn | USA | 0 |
NCT03690115 | Phase II | Ponatinib | Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO) | Active, not recruiting | FRA | 0 |
NCT06317649 | Phase II | Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Recruiting | USA | 1 |
NCT04336982 | Phase Ib/II | Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | Terminated | USA | GBR | FRA | CAN | BEL | 0 |
NCT03552029 | Phase I | Milademetan + Quizartinib | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02668653 | Phase III | Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) | Completed | USA | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 10 |
NCT04872478 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | Recruiting | USA | 0 |
NCT03250338 | Phase III | Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | Unknown status | USA | ITA | FRA | ESP | DEU | CAN | 0 |
NCT05010122 | Phase Ib/II | Decitabine and Cedazuridine + Gilteritinib + Venetoclax | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02039726 | Phase III | Cytarabine + Fludarabine Cytarabine + Etoposide + Mitoxantrone Quizartinib Filgrastim + Idarubicin | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | Completed | USA | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 5 |
NCT03513484 | Phase I | Azacitidine + Nintedanib | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT06235801 | Phase Ib/II | Gilteritinib + Momelotinib | A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03793478 | Phase Ib/II | Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | Active, not recruiting | USA | SWE | NLD | ITA | ISR | FRA | ESP | DNK | CAN | BEL | 0 |
NCT06578247 | Phase III | Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Quizartinib | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (QuANTUM-WILD) | Not yet recruiting | USA | SWE | ROU | POL | NOR | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 8 |
NCT04209725 | Phase II | CPX-351 + Quizartinib | A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT05520567 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04240002 | Phase Ib/II | Cytarabine + Filgrastim + Fludarabine + Gilteritinib | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT02752035 | Phase II | Gilteritinib Azacitidine + Gilteritinib Azacitidine | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT01892371 | Phase Ib/II | Azacitidine + Quizartinib Cytarabine + Quizartinib | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02997202 | Phase III | Gilteritinib | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | Completed | USA | POL | NZL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 3 |
NCT02400255 | Phase II | Crenolanib | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | Completed | USA | 0 |
NCT05546580 | Phase I | Gilteritinib + ORY-1001 | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) | Recruiting | USA | 0 |
NCT02927262 | Phase III | Gilteritinib | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | Completed | USA | SWE | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | 5 |
NCT02270463 | Phase Ib/II | Tagraxofusp-erzs | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | Terminated | USA | 0 |
NCT02335814 | Phase I | FLX925 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03512197 | Phase III | Daunorubicin + Midostaurin Cytarabine + Idarubicin + Midostaurin Cytarabine + Idarubicin Daunorubicin | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | Completed | USA | TUR | POL | NOR | ITA | ISR | FRA | ESP | DEU | CZE | CHE | BRA | BGR | BEL | AUT | AUS | ARG | 3 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
NCT03904069 | Phase I | Anti-FLT3 CAR-T cells | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Withdrawn | USA | 0 |
NCT06325748 | Phase I | SENTI-202 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Recruiting | USA | AUS | 0 |
NCT01398462 | Phase I | CWP232291 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Completed | USA | 1 |
NCT01266083 | Phase II | WT1 vaccine | Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |